Document:

EX-10.12

 Exhibit 10.12 

***Certain confidential information 

contained in this document, marked by 

brackets, has been omitted and filed 

separately with the Securities and 

Exchange Commission pursuant to Rule 

406 of the Securities Act of 1933, as amended. 

Execution Version 
 LICENSE
AGREEMENT 
 between 
 Helmholtz-Zentrum München -
Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH 
 Ingolstädter Landstraße 1 

85764 Neuherberg 
 Germany 

– in the following: “HMGU” – 

and 
 Poseida Therapeutics, Inc. 

4250 Executive Square, Suite 900 
 La Jolla, CA 92037 

U.S.A. 
 – in the following:
“POSEIDA” or “LICENSEE” – 
 – The LICENSEE and HMGU individually a “Party” and
collectively the “Parties” – 

  
 1 

 Preamble 

HMGU is a public research institution operating in the field of environmental health. Researchers at HMGU identified the endonuclease “Clo51” from
the bacterial strain [...***...] as an enzyme that can be used for genome editing purposes (hereinafter referred to as the “ORIGINAL MATERIAL”) as described in Annex 1. The technology involving the ORIGINAL MATERIAL is protected by
the [...***...]. 
 LICENSEE is a cell and gene therapy company developing human therapeutics based on its proprietary genome editing technologies.

 On June 2, 2015, HMGU, LICENSEE, Transposagen Biopharmaceuticals, Inc. (“TRANSPOSAGEN”), and Hera Testing Laboratories, Inc.
(“HERA”) concluded a Material Transfer and Option Agreement (the “OPTION AGREEMENT”), by means of which HMGU granted the LICENSEE, TRANSPOSAGEN and HERA access to the ORIGINAL MATERIAL for purposes of evaluating it, as well as an
option for an exclusive commercial license to the PATENT RIGHTS (the “OPTION”). 
 The LICENSEE, TRANSPOSAGEN and HERA have evaluated the ORIGINAL
MATERIAL and have exercised the OPTION as stipulated in the OPTION AGREEMENT. HMGU is willing to grant licenses accordingly. Concurrent with the execution of this Agreement, TRANSPOSAGEN and HMGU are entering into a license agreement (the
“TRANSPOSAGEN AGREEMENT”) and HERA and HMGU are entering into a license agreement (the “HERA AGREEMENT”). 
 Now, therefore, the Parties
agree as follows: 
  

	§ 1	 Definitions 

  

	1.1	 “COMBINATION PRODUCT” means [...***...]. The other active ingredient(s) in clause (a) and
the other pharmaceutical product(s) in clause (b) are each referred to as the “Other Product(s)”. 

  

	1.2	 “CONFIDENTIAL INFORMATION”: The term ‘CONFIDENTIAL INFORMATION’ shall mean any information,
data or substance exchanged among the Parties under this Agreement, irrespective of the form of transmission (e.g. orally, in written form, electronically). 

  

	1.3	 “CONTRACT YEAR”: The term ‘CONTRACT YEAR’ shall mean a calendar year. The first CONTRACT
YEAR shall run from the EFFECTIVE DATE to the end of the respective calendar year. 

  

	1.4	 “EFFECTIVE DATE” shall be the date on which this Agreement is signed by the last Party.

  

	1.5	 “LICENSED PRODUCT”: The term ‘LICENSED PRODUCT’ shall mean any product which itself or the
production of which, absent the license granted hereunder, would infringe at least one Valid Claim. “Valid Claim” shall be a claim of (a) a patent covered by the definition of PATENT RIGHTS, or (b) a claim of a published pending
patent application within the scope of PATENT RIGHTS, provided that 

  
  

***Certain Confidential Information Omitted 
  

2 

	 	
such application confers provisional protection and has not been withdrawn, abandoned or finally rejected without possibility of appeal or re-filing.

  

	1.6	 “LICENSED SERVICE” shall mean any service which, absent the license granted hereunder, would infringe
at least one Valid Claim as defined in Section 1.5. 

  

	1.7	 “MATERIAL” comprises ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES and MODIFICATIONS.

  

	1.8	 “MODIFICATIONS” are modifications of the ORIGINAL MATERIAL, PROGENY and/or UNMODIFIED DERIVATIVES
which contain or incorporate ORIGINAL MATERIAL, PROGENY and/or UNMODIFIED DERIVATIVES, in whole or in part. 

  

	1.9	 “NET SALES” shall mean the gross amount invoiced by LICENSEE or sublicensees on account of a first
sale or other commercial use of LICENSED PRODUCTS and LICENSED SERVICES, less the following deductions: 

[...***...] 
 If first sale
is made to a third party which is an Affiliate of a sublicensee of a LICENSEE or of a LICENSEE, the invoice price shall be adjusted in order to reflect the invoice price of transactions with a non-affiliated third party. “Affiliates”
within the meaning of this paragraph shall be any legal entities that (directly or indirectly) control, are controlled by, or are under common control with a Party, whereby the controlling entity controls at least 50 per cent of the voting equity
interests. 
 As used in this Agreement, first sale or other commercial use shall not include use of LICENSED PRODUCTS or LICENSED SERVICES
for use in clinical study purposes or compassionate use programs. 
 NET SALES of a COMBINATION PRODUCT shall be calculated as follows: 

[...***...] 

  
  

***Certain Confidential Information Omitted 
  

3 

	1.10	 “ORIGINAL MATERIAL” comprises plasmid DNA as described in Annex 1. 

 

	1.11	 “PATENT RIGHTS” shall mean [...***...], including any patents issuing from such patent
applications and any applications or patents based upon any of such patent applications or patents, as well as any continuations, divisions, re-examinations, reissues, substitutes, renewals, extensions,
supplementary protection certificates of any of the foregoing patent applications or patents. 

  

	1.12	 “FIELD” shall be all fields and uses (products, services, technologies) except for

 [...***...] 
  

	1.13	 “PROGENY” is the next and all other generations of the ORIGINAL MATERIAL, which come into being by
any sort of biological or chemical reproduction, including but not limited to sexual, asexual and artificial reproduction, e.g. descendants of rats/mice or cells which are produced by cell division. 

 

	1.14	 “UNMODIFIED DERIVATIVES” are substances which constitute an unmodified functional subunit or product
expressed by the ORIGINAL MATERIAL and/or PROGENY, e.g. subclones of unmodified cell lines, purified or fractionated subsets of the ORIGINAL MATERIAL or proteins expressed by DNA/RNA. 

 

	§ 2	 Use of MATERIAL by LICENSEE 

 

	2.1	 The LICENSEE has already obtained ORIGINAL MATERIAL from HMGU pursuant to the OPTION AGREEMENT. HMGU shall be
and remain owner of the ORIGINAL MATERIAL. 

  

	2.2	 The LICENSEE shall use the ORIGINAL MATERIAL in compliance with all laws and regulations applicable in the
LICENSEE’S place and country, including guidelines for work with recombinant DNA. The ORIGINAL MATERIAL is experimental in nature and shall not be used in animals, unless - where applicable - explicitly admitted by an ethics committee or
regulations on the treatment of laboratory animals, and not in humans. 

  

	2.3	 The LICENSEE shall have the right to use the MATERIAL in its FIELD in order to exercise (and consistent with)
the license granted in Section 3.1 below. In case of sublicensing according to Section 3.2 below, each sublicensee shall have the right to use the MATERIAL solely in order to exercise the sublicense. Third party contractors and service
providers performing services on behalf of LICENSEE shall have the right to use the MATERIAL solely in order to perform services for LICENSEE consistent with the license granted in Section 3.1 below. For clarity, LICENSEE shall have the right
to sell LICENSED PRODUCTS to third parties in accordance with the license granted in Section 3.1 below. 

  
  

***Certain Confidential Information Omitted 
  

4 

	2.4	 Upon any early termination of this Agreement, the LICENSEE shall immediately refrain from using the MATERIAL to
the extent covered by an issued patent within the PATENT RIGHTS and shall destroy or transfer to HMGU at HMGU’s request the foregoing MATERIAL in its possession at the time of the termination or request respectively. Such destruction and nonuse
shall be immediately confirmed to HMGU. Upon any early termination of this Agreement, end users that purchased LICENSED PRODUCTS prior to such termination shall not be obligated to return any MATERIAL embedded within the LICENSED PRODUCT.

  

	2.5	 In case of early termination with a patent for a certain jurisdiction within the PATENT RIGHTS not yet being
issued, when and if a patent within such jurisdiction within the PATENT RIGHTS issues, LICENSEE shall pay [...***...] remuneration, retroactively upon grant of the respective patent. Such remuneration shall cover LICENSEE’s commercial use
of the MATERIAL from the day of effectiveness of termination until grant of the respective patent. 

 It is understood that
LICENSEE is not allowed to sell or otherwise commercially use the MATERIAL covered by an issued patent within the PATENT RIGHTS, from the day the respective patent is issued, without a respective license from HMGU. 

 

	2.6	 Upon expiration of this Agreement, the LICENSEE shall continue to have the right to use the MATERIAL in its
possession. 

  

	§ 3	 License Grant 

 

	3.1	 HMGU hereby grants LICENSEE the exclusive right to use and practice the PATENT RIGHTS in order to research,
develop, make, use, offer for sale and sell LICENSED PRODUCTS and LICENSED SERVICES in the FIELD. 

  

	3.2	 LICENSEE may sublicense the rights granted to it in Section 3.1 to third parties through multiple tiers,
provided that in each case the respective sublicensee assumes all obligations of the LICENSEE under this agreement in a written statement to HMGU, in particular reporting and payment obligations while leaving LICENSEE’s obligations unaffected;
with regard to financial obligations, the respective LICENSEE’s and sublicensee’s obligations shall be joint and several. In addition, LICENSEE may grant non-exclusive research licenses, i.e. for
further development and/or improvement of existing and/or for the development of novel LICENSED PRODUCTS, to TRANSPOSAGEN or HERA, provided that such sublicense shall ensure that the payments to HMGU are equal to the payments the sublicensee would
have to make to HMGU if it was a direct licensee of HMGU with respect to the subject matter of the research license. LICENSEE will inform HMGU about ongoing negotiations with a potential sublicensee and will forward a copy of any sublicense
agreement to HMGU subject to the right to redact sensitive information within such agreement that is not necessary for HMGU to enforce its rights hereunder. LICENSEE will remain responsible for each of its respective sublicensees’ compliance
with the terms of this Agreement as well as sub-sublicensees’ compliance with the terms of this Agreement through applicable tiers. 

 

	3.3	 HMGU retains a free of charge, non-exclusive, sublicensable and
irrevocable right to use the PATENT RIGHTS for non-commercial research purposes, including in research collaborations with academic and commercial partners. HMGU may also provide the ORIGINAL MATERIAL to third
parties for non-commercial research purposes, including in research cooperations with not-for-profit institutions and companies
on the basis of a research MTA. The LICENSEE acknowledges that the 

  
  

***Certain Confidential Information Omitted 
  

5 

	 	inventor [...***...] has been granted the right to use the MATERIAL for his research at [...***...]. 

  

	3.4       (i)	 LICENSEE shall use [...***...] efforts to develop or have developed at least one LICENSED PRODUCT and/or
LICENSED SERVICE, as the case may be, and to obtain the necessary regulatory approvals in the major market countries (US, EU) as far as required and to market and sell LICENSED PRODUCTS and/or LICENSED SERVICES. 

 

	            (ii)	 Within [...***...] from the EFFECTIVE DATE, LICENSEE shall obtain a preclinical proof of principle
demonstrating that the Clo51-technology is suitable for cell or gene therapy approaches. In case the preclinical proof of principle cannot be demonstrated by LICENSEE within the abovementioned period, LICENSEE and HMGU shall discuss amicably
possible measures to overcome the respective problems. 

  

	            (iii)	 In addition, LICENSEE shall have initiated a phase I/II clinical study involving the Clo51-technology within
[...***...] years after the EFFECTIVE DATE. HMGU is allowed to change the exclusive license to the PATENT RIGHTS to a non-exclusive license by written notice to LICENSEE, if LICENSEE cannot achieve
clinical use of the Clo51-technology within the aforementioned time. 

  

	3.5	 On March 1st of each CONTRACT YEAR, LICENSEE shall submit
to HMGU a written report specifically stating the measures taken and the progress made in order to achieve the development goals defined in Section 3.4. 

  

	3.6	 LICENSEE hereby grants to HMGU a non-exclusive, royalty-free, non-sublicensable, non-transferrable, non-commercial research license, including for research use in
co-operations with other universities or research institutions, to new developments, modifications and improvements of the technology covered by the PATENT RIGHTS, to the extent such new developments,
modifications or improvements could not be practiced without the PATENT RIGHTS and are created by LICENSEE or any of its sublicensees; provided, that such license will not include rights to commercially use LICENSED PRODUCTS or LICENSED SERVICES
themselves. 

  

	§ 4	 Remuneration 

  

	4.1	 As remuneration for the rights granted in § 3, LICENSEE shall pay to HMGU an execution fee, annual
maintenance fees, royalties and milestone fees. Except as expressly stated in this Agreement, none of the payments shall be credited to any other payment. All payments are non-refundable.

  

	4.2	 License Execution Fee 

For execution of this Agreement, LICENSEE shall pay to HMGU € 10,000.00. Payment of the execution fee shall be due [...***...]
after the EFFECTIVE DATE and receipt of an invoice. 
  

	4.3	 Annual Maintenance Fee 

LICENSEE shall pay to HMGU an annual maintenance fee of € [...***...] for each CONTRACT YEAR. The maintenance fee shall be
credited against royalties due for the same CONTRACT YEAR. The maintenance fee for the first CONTRACT YEAR shall be due [...***...] after the EFFECTIVE DATE and shall be calculated pro rata based upon the number of months in which this
Agreement will be effective during that CONTRACT YEAR. The annual maintenance fees will be invoiced by HMGU at 

  
  

***Certain Confidential Information Omitted 
  

6 

 
the end of January of each CONTRACT YEAR and shall be paid by LICENSEE within [...***...] after receipt of the invoice. 

 

	4.4	 Royalties 

LICENSEE shall pay royalties to HMGU during the Royalty Term (defined below), on a country by country basis for a LICENSED PRODUCT and/or
LICENSED SERVICES sold by LICENSEE (with sales by a sublicensee of a LICENSEE governed by Section 4.7), according to the following scheme: 
  

	 	4.4.1	 For sale or other commercial use of LICENSED PRODUCTS and LICENSED SERVICES except therapeutics and therapeutic
use (hereinafter “CATEGORY A”): 

  

	 	a)	 Products: [...***...]% on NET SALES; and 

 

	 	b)	 Services: [...***...]% on NET SALES. 

 

	 	4.4.2	 For LICENSED PRODUCTS which are therapeutics (human or veterinary) and LICENSED SERVICES for therapeutic use
(human or veterinary) (hereinafter “CATEGORY B”): 

  

	 	a)	 Clo51 nuclease is part of the therapeutic agent (e.g. CRISPR-Clo51 gene therapy): [...***...]% on NET
SALES; and 

  

	 	b)	 Clo51 nuclease is not part of the therapeutic agent but was used to generate the therapeutic agent (e.g. cell
therapy): [...***...]% on NET SALES. 

 The Royalty Term for a country shall mean the period commencing on first
commercial sale or other commercial use in such country and ending on the expiry of the last to expire VALID CLAIM in such country. For clarity, royalties payable by LICENSEE in respect of any sublicensee sales is covered by Section 4.7. 

 

	4.5	 Due Date for payment of royalties 

Royalties shall be due annually, [...***...] after the end of a CONTRACT YEAR during the Royalty Term. If this Agreement is terminated
before the end of a CONTRACT YEAR, the royalties shall be due [...***...] after termination has become effective. 
  

	4.6	 Milestones 

  

	 	4.6.1	 LICENSEE shall make the following one-time milestone payments to HMGU
upon first achievement of each of the following events for the first LICENSED PRODUCT where the Clo51 nuclease is part of the therapeutic agent (e.g., CRISPR-Clo51 gene therapy): 

 

	 	a)	 € [...***...] 

 

	 	    	 Beginning of a clinical phase I trial for a LICENSED PRODUCT; 

 

	 	b)	 € [...***...] 

 

	 	    	 Beginning of a clinical phase II trial for a LICENSED PRODUCT; 

 

	 	c)	 € [...***...] 

 

	 	    	 Beginning of a clinical phase III trial for a LICENSED PRODUCT; 

In case of a), b) and c), “Beginning” shall mean the first treatment of a patient with a LICENSED PRODUCT; 

 

	 	d)	 € [...***...] 

 

	 	    	 Approval in USA; and 

 

	 	e)	 € [...***...] 

 

	 	    	 Approval in Europe. 

  

	 	4.6.2	 LICENSEE shall make the following one-time milestone payments to HMGU
upon first achievement of each of the following events with respect to the first LICENSED PRODUCT where the Clo51 nuclease is not part of the therapeutic (e.g. T-cell therapy): 

  
  

***Certain Confidential Information Omitted 
  

7 

	 	a)	 € [...***...] 

 

	 	    	 Beginning of a clinical phase I trial for a LICENSED PRODUCT 

 

	 	b)	 € [...***...] 

 

	 	    	 Beginning of a clinical phase II trial for a LICENSED PRODUCT; 

 

	 	c)	 € [...***...] 

 

	 	    	 Beginning of a clinical phase III trial for a LICENSED PRODUCT. 

In case of a), b) and c), “Beginning” shall mean the first treatment of a patient with a LICENSED PRODUCT; 

 

	 	d)	 € [...***...] 

 

	 	    	 Approval in USA; and 

 

	 	e)	 € [...***...] Approval in Europe. 

 

	 	4.6.3	 All Milestone payments become due irrespective of whether the respective milestone has been reached by LICENSEE
or any of its sublicensees. A milestone event shall also have occurred if a collaboration partner of LICENSEE or a sublicensee of LICENSEE (in each case to whom rights have been provided to LICENSED PRODUCTS and/or in case the respective LICENSED
PRODUCTS have been produced by or on behalf of LICENSEE or a sublicensee of LICENSEE) is conducting the clinical trial or achieving the approval, as the case may be, on behalf of or under control of LICENSEE or a sublicensee of LICENSEE.

  

	 	4.6.4	 LICENSEE will inform HMGU immediately in writing when one of the milestones has been reached. Milestone
payments are due within [...***...] after the milestone has been reached. HMGU may and – upon request by LICENSEE – shall issue an invoice for such payment. 

 

	4.7	 In case of sublicensing, LICENSEE shall pay to HMGU 

 

	 	4.7.1	 For CATEGORY A: 

  

	 	a)	 In case of sales or other commercial use of a LICENSED PRODUCT by a sublicensee, [...***...]% on NET
SALES invoiced by sublicensee; and 

  

	 	b)	 In case of sales or other commercial use of a LICENSED SERVICE by a sublicensee, [...***...]% on NET
SALES invoiced by sublicensee; and 

  

	 	c)	 [...***...]% of other payments (execution fee, milestones, payments in consideration of the issuance of
equity, etc., but excluding royalty payments, loans, profit sharing payments (so long as LICENSEE pays the NET SALES royalties in Section 4.4 on LICENSED PRODUCT and/or LICENSED SERVICE NET SALES), cost-covering supply reimbursement and
cost-covering reimbursements for research or development activities) received by LICENSEE from a sublicensee as a quid pro quo for the grant of the sublicense (hereinafter “Other Payments”) 

 

	 	4.7.2	 For CATEGORY B: 

  

	 	a)	 If Clo51 nuclease is part of the therapeutic agent: 

i) In case of sales or other commercial use of a LICENSED PRODUCT or a LICENSED SERVICE by a sublicensee, [...***...]% on NET SALES
invoiced by sublicensee; and 
 ii) [...***...]% of Other Payments. 

 

	 	b)	 If Clo51 nuclease is not part of the therapeutic agent but was used to generate the agent:

 i) In case of sales or other commercial use of a LICENSED PRODUCT or a LICENSED SERVICE by a sublicensee,
[...***...]% on NET SALES invoiced by sublicensee; and 
 ii) [...***...]% of Other Payments. 

  
  

***Certain Confidential Information Omitted 
  

8 

	4.8	 All payments under this § 4 shall be made to the following account: 

 

			
	Account holder:	  	Ascenion GmbH
	Bank name:	  	Commerzbank Muenchen
	SWIFT CODE	  	[ *** ]
	IBAN (Account Number)	  	[ *** ]

 HMGU has authorized Ascenion GmbH to collect and receive the payments which become due under this Agreement.

  

	4.9	 Notwithstanding other rights of HMGU, late payments will be charged with a fee at the annual rate of
[...***...]. 

  

	4.10	 On all payments under this § 4, the LICENSEE will pay VAT in the statutory amount should VAT apply.

  

	§ 5	 Accounts, Reporting and Audits 

 

	5.1	 LICENSEE shall keep, and shall cause its sublicensees to keep, complete and accurate records according to
general accounting principles and containing all the data reasonably required for the full computation and verification of the payments to be made under § 4. As part of the records, LICENSEE will keep for a period of [...***...] years
originals or copies of the invoices sent to its sublicensees and/or purchasers/recipients of LICENSED PRODUCTS and LICENSED SERVICES. 

  

	5.2	 HMGU is entitled to inspect LICENSEE’S records and to direct the LICENSEE to inspect any of its
sublicensees’ records, with [...***...] prior written notice not more than [...***...] a year during business hours, by an independent auditor or other member of a profession which is under a professional duty of confidentiality,
elected by HMGU. The cost of such inspection shall be borne by HMGU. If the inspection shows that the payments made by LICENSEE differ to HMGU’s disadvantage by more than [...***...]% ([...***...] percent) from the payments which
were actually due, the LICENSEE shall bear the costs of the inspection. 

  

	5.3	 Annually, within [...***...] after the end of each half CONTRACT YEAR, LICENSEE shall forward to HMGU
a report reflecting the payments due under § 4 on a LICENSED PRODUCT-by-LICENSED PRODUCT, LICENSED SERVICE-by-LICENSED SERVICE and country-by-country basis. The report shall state all transactions with each purchaser/recipient
of LICENSED PRODUCTS and/or LICENSED SERVICES and each of the LICENSEE’S licensees, showing the NET SALES (whichever is relevant for the calculation of remuneration/royalties) attributed to the transaction. If no payment is due, a report
certifying this shall be supplied. If this Agreement is terminated before the end of a CONTRACT YEAR, the report shall be due within [...***...] after the termination has become effective. The correctness and completeness of the report shall
be certified by LICENSEE’s chief financial officer. 

  

	§ 6	 Ownership; Patent Filing, Prosecution and Litigation 

 

	6.1	 HMGU remains owner of the PATENT RIGHTS, irrespective of their use by the LICENSEE, and the patent records
remain in the name of HMGU as applicant. Unless HMGU notifies LICENSEE otherwise in writing (Email is sufficient), HMGU authorizes LICENSEE to conduct patent prosecution, maintenance and patenting strategy within its own reasonable discretion but in
cooperation with HMGU. 

  
  

***Certain Confidential Information Omitted 
  

9 

 LICENSEE shall inform HMGU about important filings, prosecution and maintenance measures.
LICENSEE acknowledges that LICENSEE, TRANSPOSAGEN and HERA are jointly and severally liable for paying the costs of filing, prosecuting, maintaining and defending the PATENT RIGHTS. Therefore, LICENSEE shall bear one third (1/3) of the costs of
filing, prosecuting, maintaining and defending the PATENT RIGHTS as long as each of TRANSPOSAGEN and HERA also bear one third (1/3) of such costs. 
  

	6.2	 With advance written notice to HMGU of at least [...***...] and respective information to TRANSPOSAGEN
and HERA in due time, LICENSEE may decide not to pay further prosecution or maintenance cost of a patent and/or patent application included within PATENT RIGHTS in any national jurisdiction(s). 

 

	6.3	 In case TRANSPOSAGEN and/or HERA make a decision subject to the respective Section 6.2 in the TRANSPOSAGEN
AGREEMENT or the HERA AGREEMENT, LICENSEE will continue to pay such cost for this/these jurisdiction(s) according to the adjusted cost split (alternatively, half the cost in case of TRANSPOSAGEN or HERA make such decision and full cost in case of
TRANSPOSAGEN and HERA make such decision) starting [...***...] after original notice of TRANSPOSAGEN and/or HERA, as the case may be, to HMGU. 

If LICENSEE, TRANSPOSAGEN and HERA each make such a decision, HMGU may decide by written notice to LICENSEE, TRANSPOSAGEN and HERA to
(i) abandon prosecution or maintenance of that patent and/or patent application within such jurisdiction(s) or (ii) pursue prosecution or maintenance of that patent and/or patent application within such jurisdiction(s) at its own cost with
LICENSEE, TRANSPOSAGEN and HERA having no further rights in and to that particular patent application or patent within such national jurisdiction(s) and HMGU being entitled to otherwise commercialize such patent application or patent, or
(iii) pursue prosecution or maintenance of that patent and/or patent application within such jurisdiction(s) at its own cost with such PATENT RIGHT to remain covered by this Agreement. 

 

	6.4	 A Party becoming aware of an infringement or other unauthorized uses of a PATENT RIGHT by any third party shall
immediately inform the other Party in writing. Generally, LICENSEE shall be entitled to take all reasonable actions to prevent or enjoin any unauthorized use of a PATENT RIGHT at its own risk and expense in the FIELD, and HMGU, upon request and at
the cost of LICENSEE, shall provide such assistance as LICENSEE may reasonably request. HMGU shall be entitled to join proceedings instituted by LICENSEE. Any recovery obtained in the course of defense of the PATENT RIGHTS shall first be used to
refund any out-of-pocket expenses, including attorney costs, incurred by the LICENSEE and, where applicable, HMGU in bringing such action. The remaining recovery, if
any, shall remain with the LICENSEE but subject to a contribution of [...***...]% to be paid to HMGU. In the event LICENSEE has not taken action against an alleged infringer within reasonable time after becoming aware of an infringement, but
at the latest [...***...] days before the expiry of any time limit whose observance is necessary in order not to prejudice the procedural situation in defending the PATENT RIGHT, HMGU may, but shall not be required to, take such action as HMGU
may deem appropriate in order to prevent or enjoin the alleged infringement. In such case, HMGU shall act at its own risk and expense, and LICENSEE shall reasonably cooperate with HMGU. Any recovery obtained under sole action of HMGU shall
[...***...]. 

  

	6.5	 The provisions of Section 6.4 shall apply accordingly if a third party challenges the validity of a PATENT
RIGHT, provided that if LICENSEE does not defend the respective PATENT RIGHT in due time at LICENSEE’S expense and the Parties 

  
  

***Certain Confidential Information Omitted 
  

10 

	 	
cannot agree to defend jointly, HMGU has the right (but not the obligation) to defend the PATENT RIGHT and with respect to such PATENT RIGHT may determine in its sole discretion to exclude the
PATENT RIGHT from the license granted in this Agreement or leave the PATENT RIGHT under the license granted to LICENSEE in which case the royalty rate for LICENSED PRODUCTS and LICENSED SERVICES distributed in the respective country shall increase
by [...***...] % until HMGU’s expenses incurred within the course of defense of the PATENT RIGHT have been reimbursed. 

  

	§ 7	 Representations, Warranties and Indemnification 

 

	7.1	 The LICENSEE shall use the MATERIAL and the PATENT RIGHTS at its own risk. All claims based on legal or other
defects of the MATERIAL and/or PATENT RIGHTS shall be excluded. In particular, HMGU is not liable if the use of the MATERIAL and/or PATENT RIGHTS infringes the rights of third parties or if the inventions which are the subject matter of the PATENT
RIGHTS are not patentable. 

  

	7.2	 HMGU declares that, to the best of its knowledge as of the EFFECTIVE DATE, (a) it is the sole owner of the
PATENT RIGHTS, (b) it has not previously assigned, conveyed or otherwise encumbered its right, title and interest in the PATENT RIGHTS in a manner that would make grant of the licenses hereunder legally impossible and (c) it has the right
to grant the license rights herein. HMGU makes no representation or warranty – whether express or implied – as to the operability or fitness for any use, safety, efficacy, approvability by regulatory authorities, time and cost of
development and/or breadth of the technology covered by the PATENT RIGHTS. 

  

	7.3	 In any case of liability for damages among the Parties, such liability is limited to foreseeable damages.
Liability for lost profits is excluded. Except as stipulated in Sections 3.2, 6.1 and 6.3 above, the obligation and liabilities of LICENSEE (including, without limitation, payment and indemnification) under this Agreement shall be sole (and not
joint and several) with respect to the acts or omissions of LICENSEE. 

  

	7.4	 LICENSEE indemnifies and holds HMGU harmless from any liability and all claims arising from LICENSEE’S use
of the MATERIAL and/or PATENT RIGHTS, including claims by third parties which are based on the allegation that such third party has been injured or harmed by a LICENSED PRODUCT and/or LICENSED SERVICE. 

 

	7.5	 HMGU on one side and the LICENSEE on the other are not acting as agents or contractors for the respective other
side. This Agreement shall not create a partnership among the Parties. 

  

	7.6	 HMGU may not use the name of the LICENSEE and LICENSEE may not use HMGU’s name for any advertisement or
promotional purpose without the prior written consent of the respective other Party. However, the Parties or their technology transfer partners shall be entitled to issue a press release informing the public about the licenses granted hereunder
without disclosing any CONFIDENTIAL INFORMATION belonging to the other Party or information that may harm the legitimate business interests of the other Party. Each Party will present to the other Party a draft Press Release within a reasonable time
period but at least [...***...] prior to the anticipated publication date. In case the other Party objects to the publication of the press release within [...***...] from receipt, the Parties will amicably and expeditiously collaborate
in order to find a version which suits both Parties’ needs. 

  
  

***Certain Confidential Information Omitted 
  

11 

	§ 8	 Confidentiality 

 

	8.1	 A Party receiving CONFIDENTIAL INFORMATION (the “Receiving Party”) from the other Party (the
“Disclosing Party”) will keep such CONFIDENTIAL INFORMATION confidential. In particular, the Receiving Party shall only use and reproduce such CONFIDENTIAL INFORMATION to the extent necessary in order to pursue the objectives of this
Agreement. Furthermore, the Receiving Party shall not disclose CONFIDENTIAL INFORMATION to any third party; this includes disclosure under a confidentiality Agreement. Ascenion GmbH is not a third party with regard to HMGU as Receiving Party.

  

	8.2	 The Receiving Party shall disclose CONFIDENTIAL INFORMATION only to such officers and employees,

  

	 	a)	 who strictly need to access such information in order to accomplish the objectives of this Agreement; and

  

	 	b)	 who are under a confidentiality obligation that is at least as strict as the obligations set forth in this
Agreement. 

  

	8.3	 The obligations under Sections 8.1 and 8.2 above shall not extend to all or any part of the CONFIDENTIAL
INFORMATION for which the Receiving Party can prove 

  

	 	a)	 that it was or became part of the public domain or publicly known without fault of the Receiving Party; or

  

	 	b)	 that it was rightfully in the possession of the Receiving Party prior to the disclosure; or

  

	 	c)	 that it was supplied to the Receiving Party by a third party which is not under a confidentiality obligation to
Disclosing Party; or 

  

	 	d)	 that Receiving Party has to disclose in response to a valid order of a court or other governmental body or
subdivision thereof, or whose disclosure is otherwise required by law or regulation (including the rules of any nationally recognized securities exchange); providing, however, that the Receiving Party shall have given reasonable prior notice to the
Disclosing Party, and that the Receiving Party shall make a reasonable effort to obtain a protective order requiring that the CONFIDENTIAL INFORMATION so disclosed be limited to information necessarily responsive to the order issued.

  

	8.4	 After any termination or expiration of this Agreement, the Receiving Party shall – upon instruction by the
Disclosing Party – return to the Disclosing Party or destroy any document or data carrier containing CONFIDENTIAL INFORMATION in its possession. If the Disclosing Party gives no instruction, the Receiving Party shall destroy any document or
data carrier containing CONFIDENTIAL INFORMATION [...***...] after any termination or expiration of this Agreement. However, one (1) copy of CONFIDENTIAL INFORMATION and automatically generated electronic backup copies may be retained in
a secure location for the sole purpose of determining compliance with ongoing obligations under this Agreement. 

  

	8.5	 The Parties’ obligations under this § 8 shall extend for a period of [...***...] years after
any termination or expiration of this Agreement. 

  

	§ 9	 Termination 

  

	9.1	 This Agreement shall come into force as of the EFFECTIVE DATE and shall run until the requirement to pay
royalties under § 4 above ends, subject only to one of the reasons for termination mentioned below. Upon expiration of this Agreement, LICENSEE shall have the right to continue to use the MATERIAL as set forth in Section 2.6.

  
  

***Certain Confidential Information Omitted 
  

12 

	9.2	 Each Party shall have the right to terminate this Agreement following any material breach by the other Party,
if the breach is not cured within six (6) weeks after notice by the non-breaching Party. A material breach by LICENSEE shall include (without limitation) the following: 

 

	 	a)	 breach of the development obligation under Section 3.4, 

 

	 	b)	 non-payment of the license fees mentioned in § 4,

  

	 	c)	 non-delivery of the reports mentioned in Section 4.6.4 or
Section 5.3, 

  

	 	d)	 breach of payment obligation under Section 6.1, or 

 

	 	e)	 challenge of the validity of a PATENT RIGHT or support of third parties in challenging the validity of a PATENT
RIGHT. 

 However, before being entitled to termination as to a), HMGU has to allow LICENSEE to cure the breach within six
months after receipt of a notice sent by HMGU. 
  

	9.3	 LICENSEE shall, without undue delay, notify HMGU in writing in case it runs into substantial financial
difficulties which are so substantial that a reasonable CEO would consider filing for insolvency proceedings over all or substantially all of the LICENSEE’s assets within the following weeks. In such a case, HMGU has the right to terminate this
Agreement vis-à-vis the LICENSEE. 

  

	9.4	 LICENSEE has the right to terminate this Agreement with three months’ notice to the end of a calendar
year; provided, that, if LICENSEE terminates this Agreement prior to December 31, 2018, then LICENSEE shall pay HMGU a termination fee equal to twenty thousand Euros (20,000 €). 

 

	9.5	 A notice of termination has to be in writing to be valid. 

 

	9.6	 This Agreement shall end automatically to the extent permitted under applicable law if LICENSEE becomes subject
to insolvency proceedings, or if LICENSEE undergoes voluntary or involuntary dissolution or suffers the appointment of a receiver or trustee over all, or substantially all of its assets, in each case which case is not dismissed within two months
after the commencement thereof. 

  

	9.7	 Any termination of this Agreement shall not affect rights and obligation which have accrued while this
Agreement was in effect. In particular, any termination of this Agreement shall not affect LICENSEE’S obligation to pay royalties and to allow book inspection (Section 5.2) with regard to payments which have become due while this Agreement has
been in effect. 

  

	9.8	 In the event of termination of this Agreement by HMGU according to Section 9.2 (i.e. for material breach
by LICENSEE), provided that a particular sublicensee of LICENSEE did not cause the breach that resulted in such termination and is not in breach of the respective sublicensee agreement, such sublicensee shall, at its election, have the right to
receive a direct license from HMGU under, at HMGU’s election, either the terms and conditions of this Agreement, to the extent applicable to the scope of the sublicense granted to such sublicensee, or the terms and conditions of the
sublicensing agreement between LICENSEE and the sublicensee, to the extent applicable to the scope of the PATENT RIGHTS sublicensed to such sublicensee. 

  

	9.9	 Sections 2.2, 7.1, 7.3 and 7.4 shall survive termination or expiry of this Agreement for as long as LICENSEE
has MATERIAL in its possession. 

  
 13 

	§ 10	 Miscellaneous 

 

	10.1	 Neither Party shall be entitled to assign this Agreement in its entirety to third parties; provided that a
Party may assign any of its rights or delegate any of its obligations under this Agreement without the consent but with prior notification to the other Party to (i) its Affiliate(s) or subsidiary(ies) or (ii) its successor in interest in
connection with any merger, acquisition, consolidation, or sale of all or substantially all of the assets of a party, provided that such assignee assumes in writing or under law all of the obligations of such Party hereunder. Except in connection
with any sublicense and as expressly stated in this Agreement, neither Party shall be entitled to delegate obligations under this Agreement to third parties. 

  

	10.2	 All communications under this Agreement shall be in writing and shall be mailed, hand delivered or faxed as
follows, unless otherwise indicated by a Party in writing: 

 If to HMGU: 

Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH 

Attention of: Innovation Management, [...***...] 

Ingolstädter Landstraße 1 

D-85764 Neuherberg 

E-mail: [...***...] 

Fax: [...***...] 
 If to
POSEIDA: 
 Attention of: Eric Ostertag, CEO 

4250 Executive Square, Suite 900 

La Jolla, CA 92037 
 USA 

E-mail: [...***...] 

Fax: [...***...] 
  

	10.3	 The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or
enforceability of any other provision hereof. In the place of the invalid provision, a valid provision is presumed to be agreed upon which comes economically closest to the one actually agreed upon. 

 

	10.4	 General terms and conditions of the Parties do not apply to the Parties’ relationship under this
Agreement. 

  

	10.5	 This Agreement contains the entire agreement of the Parties. There are no oral side agreements. The provisions
of this Agreement cannot be changed, modified, amended or waived except by a written instrument signed by the Parties. This also applies to a waiver of this form provision. 

 

	10.6	 This Agreement shall be governed by the laws of Germany with the exception of its conflict of law rules
resulting in the application of a foreign jurisdiction and under exclusion of the UN Convention on the International Sale of Goods. For all controversies arising under this Agreement, the courts of the city of Munich, Germany shall have exclusive
jurisdiction to which the Parties hereby irrevocably submit. 

  
  

***Certain Confidential Information Omitted 
  

14 

 This Agreement has been executed in two original versions, one belonging to each Party. 

For and on behalf of HMGU 
  

									
	Signature	  	 /s/ [...***...]
	  		  	Place, Date	  	Neuherberg 20.05.16
	Name	  		  		  		  	
	Affiliation	  		  	                    	  		  	
					
	Signature	  	 /s/ [...***...]
	  		  	Place, Date	  	Neuherberg 20.05.16
	Name	  		  		  		  	
	Affiliation	  		  		  		  	
	
	For and on behalf of POSEIDA
					
	Signature	  	 /s/ Eric Ostertag
	  		  	Place, Date	  	5-10-16
	Name	  	Eric Ostertag	  		  		  	
	Affiliation	  	CEO	  		  		  	

  
  

***Certain Confidential Information Omitted 
  

15 

 Annex 1: The ORIGINAL MATERIAL 

Description of the ORIGINAL MATERIAL 
 [...***...]

  
  

***Certain Confidential Information Omitted 
  

16Exhibit

Exhibit 10.1

AMENDMENT TO EMPLOYMENT AGREEMENT
This Amendment (the “Amendment”) is executed December 31, 2018, by and between Chesapeake Energy Corporation (the “Company”), and Robert D. Lawler (the “Executive”).
WHEREAS, the Company and the Executive entered into an employment agreement effective July 1, 2013 and amended the employment agreement June 16, 2016 (the “Employment Agreement”); and
WHEREAS, the Company and the Executive desire to amend the Employment Agreement to extend the Term.
NOW, THEREFORE, in consideration of the promises and mutual agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:
1.Capitalized Terms.  All capitalized terms used in this Amendment and not otherwise defined shall have the same meaning in this Amendment as in the Employment Agreement.
2.Amendment to Employment Agreement.
The first sentence of Section 5 of the Employment Agreement is amended to provide as follows:
The term of Executive’s employment under the provisions of this Agreement shall be for a period commencing on the Effective Date and ending on December 31, 2021 (the “Term”); provided, however, that the Term shall automatically be extended thereafter for successive periods of one year unless, at least one hundred twenty (120) days prior to the expiration of the then current Term, either party shall have given written notice to the other of the intention not to extend the Term (a “Notice of Nonrenewal”); and provided, further, that if during the Term of this Agreement a Change of Control occurs, the Term of this Agreement shall be extended to the later of the original expiration date of the Term or the expiration of the Change of Control Period; and provided, further, that if the Company provides a Notice of Nonrenewal to the Executive in accordance with this Section 5 and terminates the Executive’s employment without Cause upon the expiration of the Term, then such termination shall be considered a termination of the Executive’s employment by the Company without Cause pursuant to Section 6.1.1(a) or 6.1.2(a), as applicable, for all purposes under this Agreement, including for purposes of the Company’s obligations to pay termination compensation in accordance with the terms of this Agreement. 

IN WITNESS WHEREOF, the Company and the Executive have executed this Amendment to be effective December 31, 2018.
	
					
	Company:
	 
	 
	CHESAPEAKE ENERGY CORPORATION

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	By:
	/s/ Merrill A. Miller, Jr.

	 
	 
	 
	 
	Name: Merrill A. Miller, Jr.
Title:    Chairman of the Compensation Committee

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	Executive:
	 
	 
	By:
	/s/ Robert D. Lawler

	 
	 
	 
	 
	Robert D. Lawler

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]